Picture supply: The Motley Idiot.
Intuitive Surgical (NASDAQ: ISRG)
This fall 2024 Earnings Name
Jan 23, 2025, 4:30 p.m. ET
Contents:
- Ready Remarks
- Questions and Solutions
- Name Individuals
Ready Remarks:
Operator
Good day, and thanks for standing by. Welcome to the This fall 2024 Intuitiveearnings convention name Presently, all individuals are in a listen-only mode. Please be suggested that right now’s convention is being recorded.
After the audio system’ presentation, there will probably be a question-and-answer session. [Operator instructions] I’d now like at hand the convention over to your speaker right now, Brandon Lamm, investor relations for Intuitive Surgical.
Brandon Lamm — Senior Supervisor, Investor Relations
Good afternoon, and welcome to Intuitive’s fourth quarter earnings convention Name. With me right now, we’ve Gary Guthart, our CEO; Jamie Samath, our CFO; Daniel Oh, our senior medical officer. Dave Rosa, our president and common participant on this name, is away from the workplace this week on a previous enterprise dedication and won’t be becoming a member of right now. Dr.
Daniel Oh, senior medical officer and practising surgeon, will be a part of us on this name to explain scientific highlights. We might additionally prefer to announce that Dan Connolly will probably be becoming a member of Intuitive as our VP and head of investor relations. Dan has labored as a world funding supervisor for the final 18 years and has actively adopted surgical robotics since 2008. We look ahead to Dan becoming a member of Intuitive in early February.
Don’t miss this second likelihood at a doubtlessly profitable alternative
Ever really feel such as you missed the boat in shopping for probably the most profitable shares? Then you definitely’ll need to hear this.
On uncommon events, our skilled staff of analysts points a “Double Down” stock advice for corporations that they assume are about to pop. If you happen to’re apprehensive you’ve already missed your likelihood to speculate, now could be the very best time to purchase earlier than it’s too late. And the numbers converse for themselves:
- Nvidia: in case you invested $1,000 after we doubled down in 2009, you’d have $381,355!*
- Apple: in case you invested $1,000 after we doubled down in 2008, you’d have $42,390!*
- Netflix: in case you invested $1,000 after we doubled down in 2004, you’d have $514,479!*
Proper now, we’re issuing “Double Down” alerts for 3 unbelievable corporations, and there might not be one other likelihood like this anytime quickly.
*Inventory Advisor returns as of January 21, 2025
Earlier than we start, I wish to inform you that feedback talked about on right now’s name could also be deemed to include forward-looking statements. Precise outcomes could differ materially from these expressed or implied because of sure dangers and uncertainties. These dangers and uncertainties are described intimately in our Securities and Trade Fee filings, together with our most up-to-date Kind 10-Ok for the fiscal yr ended December thirty first, 2023, and subsequent filings. Our SEC filings could be discovered by our web site or on the SEC’s web site.
Buyers are cautioned to not place undue reliance on such forward-looking statements. Please observe that this convention name will probably be out there for audio replay on our web site at intuitive.com within the occasions part beneath our investor relations web page. In the present day’s press launch and supplementary monetary knowledge tables have been posted on our web site. In the present day’s format will encompass offering you with highlights of our full yr and fourth quarter outcomes as described in our press launch introduced earlier right now, adopted by a question-and-answer session.
Gary will current enterprise and operational highlights. Jamie will present a assessment of our monetary outcomes and process highlights. Dan will current scientific highlights. Then I’ll present our monetary outlook for 2025.
And eventually, we’ll host a question-and-answer session. With that, I will flip it over to Gary.
Gary S. Guthart — Chief Govt Officer and Director
Thanks for becoming a member of us right now. I will contact on our efficiency for the complete yr 2024 and share our perspective going into 2025. 2024 was a robust yr for Intuitive with strong early adoption of our fifth-generation multiport platform, da Vinci 5, and wholesome process progress in a lot of our supported indications in nations, leading to robust monetary efficiency for the yr. Adoption of our Ion and da Vinci SP platforms continued with new world clearances and elevated utilization.
Our groups have been onerous at work launching da Vinci 5 and studying from its early expertise. We’re bettering our merchandise throughout all three of our platforms and serving to our clients obtain their programmatic targets. We began 2024 centered on 4 major thrusts. First, we expanded indications and launches of our new platforms by area, with a specific deal with our first part of da Vinci 5 launch.
Second, we pursued elevated adoption of centered procedures by nation by coaching, business actions, and market entry efforts. Third, we drove high quality and gross margin enhancements in our world operations. And eventually, we centered on growing our productiveness, significantly in capabilities that profit from industrial scale. Taken collectively, our staff made wonderful progress in opposition to these targets.
Transferring to procedures. Development for the complete yr was 17%. Areas of energy included normal surgical procedure in america and regional efficiency in nations, together with the U.Ok. and Eire, Japan, and Germany.
Distribution markets, together with Brazil, Spain, and Italy have been additionally robust within the yr. This week, we introduced the acquisition from ab medica of the da Vinci enterprise in Italy, Spain, Portugal, and associated territories. We’re happy with their efficiency, and we look ahead to welcoming these new workers to our staff. Within the U.S., normal surgical procedure process progress was led by cholecystectomy with foregut and appendectomy procedures rising as effectively.
Thoracic process progress was additionally wholesome within the yr. Bariatric procedures fell modestly for the complete yr 2024, given the rise in GLP-1 drugs. Process progress outdoors america continued to diversify past urology with good progress in classes together with normal surgical procedure and thoracic surgical procedure. Globally, benign indications grew roughly 200 foundation factors quicker within the yr than most cancers indications.
In versatile robotics, Ion procedures confirmed continued energy with 78% progress for the complete yr. SP process progress accelerated within the yr with 72% progress over a full yr, a results of wholesome progress in Korea, Japan, and Europe and stable progress within the U.S. On the capital entrance, we positioned 1,432 port techniques within the full yr 2024, in contrast with 1,313 multiport techniques in 2023. Ion placements for the complete yr have been 271, versus 213 prior yr.
And SP placements have been 96 for the complete yr, versus 57 techniques within the prior yr. Globally, placements have been robust in america, helped by the launch of da Vinci 5. General, our techniques portfolio of da Vinci 5, da Vinci Xi, da Vinci X, da Vinci SP and Ion, mixed with our versatile financing choices permits our staff to fulfill our clients’ various wants. Jamie will take you thru placement dynamics in additional element later within the name.
System utilization stays an necessary indicator of buyer well being as a result of it’s correlated to affected person demand, care staff satisfaction, and hospital monetary well being. Multiport utilization grew 3% within the yr. SP utilization grew 12% within the yr, and Ion utilization grew 13%. Given our totally different platforms, their process combine, and websites of care, teasing aside system utilization by buyer section turns into more and more necessary going ahead.
For instance, in a midsized group hospital lung program, techniques utilization can differ from a high-volume group hospital normal surgical procedure program. As robot-assisted surgical procedure strikes to the again half of adoption curves and a few procedures, utilization progress charges could differ from prior-year traits. Our efficiency supported income of $8.4 billion for the yr, of which 84% was recurring and representing 17% progress over 2023. Our working bills have been on the decrease finish of our spend steerage.
Our spending displays three initiatives. First, we proceed to put money into R&D to assist innovation and adoption of our platforms and digital instruments globally. Second, we’re increasing our manufacturing and business footprints. And lastly, we’ve sought to leverage our enabling capabilities given our elevated scale.
Our revenue margins additionally began to enhance within the yr as elevated cargo quantity allowed for higher manufacturing unit utilization, in addition to leverage in our part cargo and different logistics prices. Taken collectively, our web earnings grew by 29% in 2024 over 2023. Touching briefly on da Vinci 5, our groups have carried out a pleasant job in executing a posh launch. We positioned 362 da Vinci 5s within the yr, and over 2,500 surgeons have carried out in complete, over 32,000 procedures on da Vinci 5 in 2024.
Da Vinci 5 has broad scientific indications and over 40 totally different process varieties have been carried out utilizing da Vinci 5 to this point. We design our techniques to permit for routine sequential upgrades to their functionality over time. And da Vinci 5 clients will obtain {hardware} and software program upgrades going ahead beginning this yr. This yr’s upgrades will deal with digital options supported by our 10,000 will increase in computing energy.
We’ll share extra particulars on these options as we carry them to market. As we enter 2025, our firm priorities are as follows. First, we’ll deal with the complete launch of da Vinci 5, its regional clearances, and follow-on function releases. Second, we’ll pursue elevated adoption of our centered procedures by nation by coaching business actions and market entry efforts.
Third, we’ll drive continued progress in constructing industrial scale, product high quality, and manufacturing optimization. And eventually, we’ll deal with excellence and availability of our digital instruments. Jamie, over to you.
Jamie E. Samath — Chief Monetary Officer
Good afternoon. I’ll describe the highlights of our efficiency on a non-GAAP or professional forma foundation, and also will summarize our GAAP efficiency later in my ready remarks. A reconciliation between our professional forma and GAAP outcomes is posted on our web site. This fall and 2024 income procedures and system placements are consistent with our preliminary press launch of January fifteenth.
I’ll briefly assessment full yr 2024 efficiency earlier than describing our This fall ends in larger element. 2024 monetary efficiency was robust. Da Vinci procedures and complete income every grew 17% over the prior yr. Professional forma gross margin improved 100 foundation factors to 69.1% and professional forma SG&A bills leveraged as in comparison with 2023.
In consequence, professional forma working margin for 2024 improved 310 foundation factors to 37%, and professional forma EPS elevated 28%, constructing off of the 22% enhance in 2023. We positioned 362 da Vinci 5 techniques in our first yr of the restricted launch, of which 174 techniques have been positioned in This fall, together with our first replacements of da Vinci 5 in Korea. Turning to This fall. Our monetary efficiency was forward of our expectations, pushed by income progress of 25% and energy throughout the remainder of the P&L, leading to professional forma working margin of 38%.
This fall income mirrored a few favorable dynamics. First, the next buy mixture of techniques as in comparison with latest intervals, pushed by multisystem offers with sure U.S. IDNs that want to buy and the next mixture of placements by distributors. Second, we noticed the next mixture of twin console placements for da Vinci 5 as we elevated provide and have been capable of assist extra educational clients.
And eventually, we noticed the next system ASP, ensuing from a stronger mixture of da Vinci 5 placements. Underlying core metrics have been additionally robust with da Vinci process progress of 18%, progress within the put in base of da Vinci techniques of 15%, and common system utilization progress of three%. In This fall, U.S. procedures grew 15%, pushed by progress in benign normal surgical procedure, together with accretive progress in procedures carried out after hours for emergent care.
Bariatric procedures within the U.S. declined within the low to mid-single-digit vary, much like final quarter. OUS procedures grew 25%, pushed by relative energy in India, the U.Ok., Italy and Japan. Process progress in Korea improved sequentially, partially pushed by robust SP progress.
Nonetheless, our enterprise there continues to be impacted by doctor strikes. Per the final couple of quarters, process progress in China was barely beneath the company common, reflecting a continuation of the dynamics we’ve described on earlier calls. Taking a look at OUS process efficiency in combination, we see robust progress in colorectal, benign normal surgical procedure, and thoracic classes. Reviewing capital efficiency.
We positioned 493 techniques within the fourth quarter, 19% greater than the 15 techniques we positioned within the fourth quarter of final yr. Within the U.S., we positioned 284 techniques in This fall, a rise of 75 techniques as in comparison with final yr, reflecting a number of giant multisystem placements with various IDNs and a rise within the provide of da Vinci 5. Outdoors the U.S., we positioned 209 techniques within the fourth quarter in contrast with 206 in the identical quarter final yr. This quarter, we positioned 89 techniques in Europe, 43 in Japan, and 20 in China in contrast with 71 in Europe, 70 in Japan, and 11 in China in This fall of final yr.
Placements within the U.Ok. and Germany proceed to be impacted by ongoing authorities finances pressures affecting healthcare capital spending. The 89 system placements in Europe included 39 techniques into markets served by our distributors as in comparison with 24 techniques final yr. In Japan, monetary pressures triggered some clients to delay capital funding choices.
Fourth quarter income was $2.41 billion, a 25% enhance over final yr. On a constant-currency foundation, income progress was 26%. Techniques income grew 36% yr over yr, pushed by a 19% enhance in da Vinci system placements, the next system ASP, and the upper buy combine beforehand referenced. Further income statistics and traits are as follows.
Leasing represented 45% of This fall placements, in contrast with 58% final quarter, pushed by the aforementioned mixture of system placements from sure IDNs within the U.S. preferring to buy and the next mixture of placements with our distributors. Nonetheless, as we glance ahead, we proceed to anticipate that leasing charges will enhance over time. This fall system common promoting costs have been $1.59 million, as in comparison with $1.42 million final yr pushed by greater mixture of da Vinci 5 and the next dual-console combine, partially offset by decrease pricing in China.
We acknowledged $28 million of lease buyout income within the fourth quarter, in contrast with $21 million final yr. Da Vinci instrument and accent income per process was roughly $1,860, in contrast with roughly $1,800 final yr. The year-over-year enhance in I&A per process displays buyer shopping for patterns and the next mixture of SP procedures, partially offset by process combine within the U.S. given a decrease mixture of bariatric procedures and the next mixture of cholecystectomy.
Turning to Ion. There have been roughly 28,000 Ion procedures carried out within the fourth quarter, a rise of 70% as in comparison with final yr. In This fall, we positioned 69 Ion techniques in comparison with 44 in This fall of 2023. As a reminder, provide constraints impacted Ion system placements within the fourth quarter of final yr.
Seven of the 69 techniques have been positioned in OUS markets. The put in base of Ion techniques elevated 51% from final yr to 805 techniques and common system utilization elevated 13% yr over yr. Fourth quarter SP process progress continued to speed up, rising 81%, pushed by Korea and early stage progress in Europe and Japan, the place we’ve clearance for a broad set of indications. We positioned 30 SP techniques in This fall and 96 for the yr, up from 57 placements in 2023.
Fourth quarter placements included 7 in Korea, 6 in Europe, and 4 in Japan. Common system utilization for our SP platform grew 18% in This fall, reflecting partially progress of SP in markets the place we’ve a broad set of indications. We’ve got acquired latest clearances within the U.S. for thoracic and colorectal indications.
Nonetheless, we anticipate broad business efforts for SP in these process classes to start as soon as we receive FDA clearance for a SP stapler. Transferring on to the remainder of the P&L. Professional forma gross margin for the fourth quarter of 2024 was 69.5%, in contrast with 68% for the fourth quarter of 2023. The year-over-year enchancment in gross margin displays mounted overhead leverage given income progress, decrease stock reserves, and enhancements in freight and logistics prices.
In 2024, we executed on our plans to considerably enhance product margins for our Ion and SP platforms. Whereas we’ve made substantial progress, Ion and SP product margins proceed to be dilutive and our groups have ongoing applications to ship additional enchancment. With respect to our manufacturing enlargement and capital funding plans. In 2025, we anticipate opening new amenities the da Vinci 5 and Ion system manufacturing in California and new endoscope manufacturing amenities in Germany and Bulgaria.
In consequence, and as we’ve beforehand indicated, we anticipate a major enhance in depreciation expense in 2025. We may also proceed to switch mature merchandise to amenities in Peachtree Corners, Georgia, and Mexicali. Given these actions, we anticipate elevated stock ranges throughout 2025. As we full this cycle of producing enlargement that’s pushed by our technique to function at industrial scale, we anticipate decrease ranges of capital expenditures in 2025 and 2026 as in comparison with latest intervals.
Fourth quarter professional forma working bills elevated 9% in contrast with final yr, pushed by elevated headcount, greater variable compensation, and elevated authorized bills. Fourth quarter 2024 working bills included a $45 million contribution to the Intuitive Basis, as in comparison with a $40 million contribution in This fall of final yr. Taking a look at working bills for the yr, we delivered on deliberate leverage in SG&A, which improved by 180 foundation factors as a share of income. Whereas we’ll proceed to search for alternatives inside SG&A to leverage as we develop, we’d spotlight that in 2025, we anticipate elevated depreciation bills given latest capital expenditures and better authorized bills given ongoing litigation.
Innovation continues to be essential to serving to our clients make progress within the Quintuple Purpose and due to this fact, it is best to anticipate us to prioritize investments in R&D. Professional forma different earnings was $87.6 million for This fall, decrease than $94.6 million within the prior quarter, primarily pushed by FX remeasurement of the stability sheet. Our professional forma efficient tax fee for the fourth quarter was 20.5%, a bit decrease than our expectations, reflecting web discrete advantages of $11 million associated to statute of limitation expirations and different changes to sure tax objects. Fourth quarter 2024 professional forma web earnings was $805 million, or $2.21 per share, in contrast with $574 million or $1.60 per share for the fourth quarter of final yr.
I’ll now summarize our GAAP outcomes. GAAP web earnings was $686 million, or $1.88 per share for the fourth quarter of 2024, in contrast with GAAP web earnings of $606 million, or $1.69 per share for the fourth quarter of 2023. As a reminder, fourth quarter 2023 GAAP tax expense mirrored one-time advantages of $159 million associated to a rise in deferred tax property related to the statutory fee enhance in Switzerland and receipt of sure tax advantages associated to our Swiss operations. The changes between professional forma and GAAP web earnings are outlined and quantified on our web site.
We ended the yr with money and investments of $8.8 billion, in contrast with $8.3 billion on the finish of Q3. The sequential enhance in money and investments mirrored money generated from working actions, partially offset by capital expenditures of $312 million. With respect to the plans, we introduced on Tuesday to go direct in Italy, Spain, Portugal, and related territories, the bottom buy value is EUR 290 million with an earn-out of as much as an extra EUR 31 million based mostly on 2025 process volumes. Whereas our major motivation is to develop nearer relationships with clients serving a mixed inhabitants of roughly 118 million folks, we do anticipate this transaction, which we estimate to shut within the first half of 2026, to be barely accretive to professional forma EPS.
Earlier than I flip it over to Dan to debate scientific highlights, let me tackle the outlook for professional forma working margins for 2025. This fall efficiency of 38% was above our expectations. Looking forward to 2025, we anticipate professional forma working margins in 2025 to be decrease than This fall because of a number of dynamics. First, as beforehand said, leasing charges are anticipated to be greater than This fall, which ends up in income and income for associated system placements to be recorded over a number of years versus within the quarter of placement.
Second, we anticipate considerably greater depreciation bills given latest capital expenditures. And eventually, we anticipate the next mixture of da Vinci 5, Ion, and SP income, which carry product margins beneath the company common. As well as, from a modeling perspective, I’d additionally spotlight a few extra issues. First, income denominated in non-USD currencies represents roughly 25% of our complete income.
On a revenue-weighted foundation, utilizing present alternate charges, the U.S. greenback is roughly 4% stronger than charges realized in This fall. Second, as we transfer into broad launch of da Vinci 5 in the midst of the yr and clients have the chance to improve their fleets, we’d anticipate buying and selling credit for Xi to be considerably greater than latest intervals adversely impacting system ASPs. Lastly, given the growing alternative clients have, as opponents carry robotic techniques to the market and search geographical clearances, we may even see capital promoting cycles lengthen as clients consider alternate options.
Brandon will present our outlook for 2025 later on this name. And with that, I wish to flip it over to Dan.
Daniel Oh — Vice President and Senior Medical Officer
Thanks, Jamie. I might prefer to share with you some lately printed peer-reviewed literature that we discovered to be notable. Along with the precise knowledge highlighted on this name, we encourage you to think about the huge physique of proof detailing these subjects in printed scientific research through the years. In the present day, we’ll give an replace on two latest publications.
Within the first examine, Dr. Rocco Ricciardi and colleagues from the Massachusetts Common Hospital in Boston collaborated with the analysis staff at Intuitive for the COMPARE examine printed within the Annals of Surgical procedure. This landmark examine in contrast perioperative outcomes of da Vinci robotic-assisted surgical procedure, to laparoscopic or thoracoscopic surgical procedure, in addition to to open procedures. This was a meta-analysis, which analyzes outcomes from beforehand printed proof over time to acquire an outline of cumulative knowledge.
On this examine, the investigators pooled knowledge from randomized managed trials, potential comparative cohort research, and huge real-world proof database research from the previous 12 years. With the intention to consider whether or not da Vinci procedures have been related to an enchancment in short-term affected person outcomes throughout seven generally carried out oncologic procedures from totally different specialties. Notably, over 1 million sufferers have been included in every of the da Vinci, laparoscopic thoracoscopic, and open affected person teams, and included knowledge from 22 nations. The authors discovered that in comparison with customary minimally invasive surgical procedure, sufferers present process da Vinci procedures had favorable perioperative outcomes.
Particularly, da Vinci sufferers had a 56% decrease likelihood of conversion to open, 21% decrease likelihood of receiving a blood transfusion, and 10% much less probability to expertise a complication inside 30 days of the process. As well as, the size of keep was considerably shorter with decrease 30-day readmission and mortality charges. Comparable favorable outcomes have been discovered for da Vinci sufferers when in comparison with the open strategy with even larger magnitude variations between the 2 approaches. The authors concluded that this meta-analysis demonstrated a number of advantages for da Vinci procedures when in comparison with various minimally invasive or open approaches, noting that these outcomes will probably be useful to decision-makers contemplating using robotics in multi-specialty settings.
Within the second examine, Dr. Michael Awad from Washington College Faculty of Medication and different colleagues printed in Surgical Endoscopy the outcomes of a preclinical examine utilizing Intuitive’s novel drive suggestions expertise included in da Vinci 5. Throughout 28 surgeons with various ranges of expertise, this examine evaluated the forces utilized to tissue when having drive suggestions expertise on or off throughout core surgical assessments, together with retraction, dissection and suturing in a tissue mannequin. Outcomes from this examine demonstrated a major discount in each the common and most forces exerted on tissue for all three surgical assessments, regardless of surgeon expertise ranges.
Notably, when utilizing the best sensitivity setting, as much as a 55% discount of the utmost drive exerted on tissue throughout suturing was noticed. The authors concluded that this examine demonstrated that drive suggestions expertise could considerably lower the forces utilized on the tissue stage when performing frequent surgical assessments throughout novice, intermediates, and skilled surgeons. They continued to notice, “This revolutionary expertise has the potential to allow safer and gentler surgical procedures, leading to higher surgical outcomes for sufferers present process robotic-assisted surgical procedure.” To me, the notable discovering on this examine is that the good thing about drive suggestions was noticed not simply in novice surgeons, which one may anticipate, but in addition in inexperienced surgeons who had accomplished a minimum of 200 da Vinci procedures. Now I will flip it over to Brandon.
Brandon Lamm — Senior Supervisor, Investor Relations
Thanks, Dan. I’ll now flip to our monetary outlook for 2025. Beginning with procedures. As described in our announcement earlier this month, complete of 2024 da Vinci procedures grew roughly 17% yr over yr to over 2,680,000 procedures carried out worldwide.
For 2025, we anticipate full yr process progress inside a spread of 13% and 16%. The low finish of the vary assumes progress in China continues to be impacted by environmental and aggressive dynamics. European governments proceed to constrain hospital capex budgets limiting the enlargement of capability within the area and bariatric process declines proceed at charges much like 2024. On the excessive finish, we assume China’s process progress recovers relative to 2024, the capex setting improves in Europe and bariatric process declines reasonably.
Q1 and full yr 2025 could have roughly one fewer working day in 2024 as a result of intercalary year. Turning to gross revenue. In 2024, our professional forma gross revenue margin was 69%. In 2025, we anticipate our professional forma gross revenue margin to be inside a spread of 67% and 68% of web income.
The decrease estimate of professional forma gross revenue margin in 2025 displays vital incremental depreciation as we carry on new amenities, the influence of progress in newer merchandise, and the influence of the stronger U.S. greenback. Our precise gross revenue margin will differ quarter to quarter relying largely on product, regional, and trade-in combine and pricing. The vary doesn’t embrace any potential influence of recent tariffs on our enterprise, which may very well be materials.
Turning to working bills. In 2024, our professional forma working bills grew 10%. In 2025, we anticipate our professional forma working expense progress to be inside a spread of 10% and 15%. The expansion in working bills displays elevated depreciation from new amenities, investments in innovation to drive our progress targets, and a rise in authorized bills.
We anticipate our noncash inventory compensation expense to vary between $760 million and $790 million in 2025. We anticipate different earnings, which is comprised largely of curiosity earnings, to complete between $370 million and $400 million in 2025. With regard to capital expenditures, we anticipate the vary to complete between $650 million and $800 million, primarily for deliberate facility development actions. With regard to earnings tax, in 2024, our professional forma earnings tax fee was 21.4%.
As we glance ahead, we estimate our 2025 professional forma earnings tax fee to be inside a spread of twenty-two% and 23% of pre-tax earnings. That concludes our ready feedback. We’ll now open the decision to your questions.
Questions & Solutions:
Operator
Thanks. [Operator instructions] Once more, yet another for our questions. Our first query comes from Larry Biegelsen with Wells Fargo. You could proceed.
Larry Biegelsen — Analyst
Good afternoon. Thanks for taking the query and congrats on a very robust end to the yr. One for Gary, one for Jamie. So, Gary, traditionally, you stated procedures drive placements within the second half of ’24.
U.S. system placements grew over 35%. Utilization was about 2%. Is that this a number one indicator of extra procedures? Or will we’ve a digestion interval to revive regular utilization? And I’ve one follow-up.
Gary S. Guthart — Chief Govt Officer and Director
Yeah. I feel a few issues are happening there. Considered one of them is as I stated within the ready remarks, as we get to the again half of some curves, the expectations of a few of these applications could also be totally different when it comes to utilization as they take part. In different phrases, not each account goes to be a high-volume account.
And I feel that is OK. I feel the economics can work and I feel we are able to provide them. So, a few of that is happening. I feel the opposite factor is new capital alternatives.
New capital options can pull ahead or in any other case have folks delay a bit bit after which purchase techniques that may put a wave or a ripple by utilization. And we’re simply going to should see if that ripple performs by. So, each of these results are possible happening. It’s truly extraordinarily onerous analytically to tease them out.
I feel within the U.S., over time, you are going to see utilization progress charges in multiport begin to settle a bit bit. I do not assume they’re going to hold galloping. On the similar time, I feel SP utilization has room to run and Ion utilization has room to run.
Larry Biegelsen — Analyst
Thanks, Gary. And Jamie, on the Q3 name, you stated the gross margin will probably be a bit decrease in 2025 versus 2024. I feel the 67% to 68% steerage was most likely a bit bit decrease than anticipated. Are you able to quantify the drivers from the 69.1% this yr in 2024 to 67% to 68%.
And the way to consider the trail again to your objective of 70%? Thanks.
Jamie E. Samath — Chief Monetary Officer
Yeah. There’s actually three drivers, Larry, the most important of which is the influence of depreciation expense and related mounted prices. So, there’s deleverage within the ’24 to ’25 comparability, roughly ish, relying on what you may have the income mannequin for ’25. That is about 1 level of the 160-point delta in case you go from ’24 precise to a midpoint of ’25.
The opposite two dynamics roughly equal-ish when it comes to influence are product combine with dV5 Ion and SP being a larger proportion of the income. All of them carry at the moment margins beneath the company common, so have a dilutive impact from a combination perspective. After which I feel what’s new from the final name is the influence of FX. So, these three issues are the drivers.
There are some offsetting price reductions. The groups are delivering inside that type of gross margin vary. I feel what we have stated with respect to gross margin is over the midterm, we predict we are able to get again past 70%. That’s going to require us, as soon as we get previous this sort of incremental depreciation to leverage over a multiyear interval as we develop.
We even have, as we have stated, the work on product margins in Ion and SP. There’s nonetheless some work to be carried out there. After which on a extra routine foundation, our groups should ship price downs.
Larry Biegelsen — Analyst
Thanks, Jamie.
Operator
Thanks. Our subsequent query comes from Robbie Marcus with J.P. Morgan. You could proceed.
Robbie Marcus — Analyst
Nice. And I will echo congratulations on a improbable fourth quarter. Two for me. First, possibly for Gary, you gave loads of element on the decision a couple of midyear full launch and trade-in cycle.
Would love to simply get your qualitative feedback round the way you’re fascinated by the combination of da Vinci 5 versus Xi going ahead. The need or the velocity at which an improve cycle can begin? And the way you are fascinated by Xi versus da Vinci 5 placements when it comes to the combination going ahead outdoors the U.S. on approval begin rolling in? All of it has implications for the mannequin, so I might like to get your ideas on that. Thanks.
Gary S. Guthart — Chief Govt Officer and Director
I used to be going to say — I will inform you a bit bit about, I feel, maybe the environmental points of that type of the wrapping round it, I will flip it over to Jamie for any modeling implications. What goes — two issues are driving what we name broad launch. Considered one of them is getting our provide chains as much as scale and quantity for what we anticipate. Demand may very well be after we begin going out and issues like trade-ins and likewise beginning to get clearances world wide.
So, that is thrilling. The subsequent one is software program updates, and people software program updates replicate each suggestions from the sector after which the combination of among the applied sciences in our digital area from hub to among the imaging issues we are able to do this begin to come out within the first set of launches, which is de facto nice. I feel these are digital instruments that our clients and surgeons will recognize and begins giving them loads of entry to knowledge that helps them analyze the efficiency of themselves and of their applications. How compelling that’s, we’ll decide how briskly clients need to improve.
I feel the improve cycle comes right down to this sort of query of differential worth. X and Xi are excellent machines. They’re workhorses. They work rather well.
We’re delighted to assist them and assist our clients who use them as they discovered the growing worth within the options and content material we carry to da Vinci 5, whether or not it is analytics or drive reflection or ergonomics or higher imaging, then that drives the buying and selling cycle. The query, and I perceive your modeling query effectively of how briskly does all of it transfer and what does that appear to be? It may be tough to foretell. Jamie, I might flip it over to you and allow you to add your commentary.
Jamie E. Samath — Chief Monetary Officer
Yeah. Whereas we do not have a selected share, the influence of transferring to broad launch, the influence of getting extra geographical clearances, clearly then says, directionally, over time, the proportion of placements which can be dV5 usually ought to enhance. Though I’d acknowledge that Xi is a succesful system. And sooner or later, we’ve the chance for a refurbished Xi.
With respect to trade-ins, you do not actually see buying and selling begin to choose up till you get to broad launch, which is the center of the yr, and it should be a perform of the dynamics that Gary indicated. In fact, we are able to look again at what occurred on the Xi launch and the way these upgrades went, and we’ve some indication from clients in our pipelines. I feel the very best that let’s imagine at this level, given it is so early is that any buying and selling cycle could be progressive.
Gary S. Guthart — Chief Govt Officer and Director
Ultimate level I will make, and I feel you had requested, Robbie, the query is a part of that is, is there a chance for depreciated property like X and Xi, that are extremely succesful? We all know the best way to service, and we all know the best way to assist or — to these open or create different alternatives in different markets which may be extra capital value delicate and the reply to that’s sure.
Robbie Marcus — Analyst
Nice. Possibly only one fast follow-up. Gary, you at all times give us a normal state of the union on the well being of the capital gear setting world wide. U.S., OUS, and I am significantly pondering of China the place you had a very robust placement quarter and fourth quarter.
So, any ideas there could be nice as we head into 2025. Thanks.
Gary S. Guthart — Chief Govt Officer and Director
Yeah. I feel Jamie often does that. Jamie, why do not you deal with that?
Jamie E. Samath — Chief Monetary Officer
I might first say I do not assume we characterised the 20 techniques we positioned in China in This fall as robust. Possibly it’s on a year-over-year comparability foundation. However the setting in China continues to be dynamic and difficult as we have stated, impacted by each home competitors and a set of actions applied by the federal government there. So, I characterize the setting as comparatively constant and difficult.
When it comes to capital total, I feel within the U.S. It has been robust. A part of that’s curiosity in da Vinci 5 given it is a new product. And also you see, to some extent, much less sensitivity to capital budgets given simply the proportion of placements within the U.S.
particularly, a minimum of. We have highlighted the challenges within the U.Ok. and Germany. And new for us in This fall for Japan was some delays due to the profitability in sure clients there.
So, I might say we have seen comparatively robust energy within the U.S., some blended dynamics within the OUS markets. We do not actually have sufficient tea leaves to foretell how that performs out in ’25.
Robbie Marcus — Analyst
Thanks very a lot.
Operator
Thanks. Our subsequent query comes from Travis Steed with Financial institution of America Securities. You could proceed.
Travis Steed — Analyst
Hey, congrats as effectively. Gary, I wished to ask a bigger-picture query. You are type of crossing over $1 billion a yr in R&D now and even after launching dV5. So, possibly assist us perceive the R&D funding alternative over the medium time period and doubtlessly transferring into type of new inexperienced area.
Is that going to be extra by than the Endoluminal platform? Or are there nonetheless chunky classes like cardio that may very well be amenable to robotics? Or is it extra in regards to the geographic enlargement aspect of care? Simply to large perceive type of the true alternative left on the market to seize.
Gary S. Guthart — Chief Govt Officer and Director
I feel it is a mixture of all three of the stuff you simply described. I feel there are improvements and applied sciences, a few of that are extensions to platforms you recognize about, a few of that are platforms which can be years away and you do not know about that I feel open new alternatives for us over time. And we’re diligent about them. They take some time.
They take some funding they usually take follow-through. There are current platforms that would use extra indications, and people could be geographic, by which case, there’s the regulatory and scientific work to safe these indications. And so, we spend cash on that and go do it. After which there’s extra indications that come from issues like extra devices and equipment and imaging capabilities on current platforms that if we develop them, we are able to carry to market and open the marketplace for others.
We additionally spent some cash ensuring that latecomers to robotics get what they want. It isn’t simply that latecomers simply want time to simmer and in the end, they arrive discover you. They often have totally different wants, whether or not these wants or studying wants or financial wants. And it takes some work.
However we predict that work is price it. And among the stuff you see in da Vinci 5 are these sorts of issues. So, brief story is that we see alternative in all of these buckets. We run a course of that tries to stability these alternatives in order that we’re not completely overexposed to at least one or the opposite, and as a substitute, we’ve a multiyear horizon and multi-specialty horizon and it is geographically blended.
Travis Steed — Analyst
Useful. After which, Jamie, possibly only a shorter-term opex query on the ten% to fifteen% progress, type of the excessive and low finish, how a lot of that is R&D versus SG&A? And any shade there on how that may form up and type of what drives the excessive and low finish? And doubtlessly, since you probably did point out tariffs. Simply type of curious the best way to measurement that or a possible approach to mitigate that, in case you can. Simply wished to type of comply with up on Larry’s margin query.
Thanks.
Jamie E. Samath — Chief Monetary Officer
Yeah. With respect to how R&D and SG&A may develop, I might characterize it as related wealthy when it comes to — for that 10% to fifteen%. Clearly, R&D is a precedence, as we have said. In SG&A, what you may see is we add reps and business of us to assist the process progress.
We even have stated that there will be greater authorized bills in SG&A given ongoing litigation and a portion of the capex outcomes and depreciation that goes into our SG&A bills. And so, they’re going to develop roughly ish about the identical fee. When it comes to the vary of 10% to fifteen%, most of that’s pushed by the process vary, that means, clearly, to some extent, we’ll handle our bills in accordance with how our enterprise performs out. There are some alternatives for us to speculate incrementally in R&D, however we’ll do this as we make progress and obtain milestones.
When it comes to tariffs, Clearly, we see rather a lot within the information the place we’re monitoring these occasions carefully. We’re internally evaluating what the influence of any potential tariff may be and due to this fact, how we’d reply. We are able to say that the numerous portion of our devices are at the moment manufactured in Mexico. And so, to the extent, there are vital tariffs applied there that would have a cloth influence for us.
And naturally, one response then that any firm may take into account is what would you do with pricing. Nothing that we have determined there. And clearly, we’re balancing the wants of our clients and their targets with the wants of our personal enterprise. So, keep tuned is what I might say.
Travis Steed — Analyst
Nice. Thanks.
Operator
Thanks. Our subsequent query comes from Rick Sensible with Stifel. You could proceed.
Rick Sensible — Analyst
Thanks. Good afternoon. Gary, in your very considerate feedback throughout the JPMorgan convention, I feel you talked about new digital options, and also you actually, right now, once more stated {hardware} and software program digital options coming. I hoped — and positive you are not prepared to provide us actually specifics on all these.
However possibly assist us perceive what areas this — in what method this may improve da Vinci 5? Will it open up new procedures? Will or not it’s about productiveness? Will or not it’s about — will it allow you to make use of the da Vinci 5 in a unique setting? How does this broaden the imaginative and prescient or the probabilities of da Vinci 5 within the close to time period? After which I will have a follow-up if I may.
Gary S. Guthart — Chief Govt Officer and Director
Yeah. In early pondering right here, simply consider it in three classes. If we are able to make it simpler to get nice outcomes for extra care groups by giving them instruments within the OR, simply real-time instruments, we predict that creates alternatives for them. I feel it builds confidence.
I feel you get higher care groups quicker that method. And this sort of — does that provide you with entry to new procedures? I feel the way in which to say that’s it most likely offers you entry to extra sufferers. Are they new process classes? Not at all times, however there are sufferers that turn out to be simpler for these surgeons and care groups to succeed in as a result of they’re extra assured to succeed in them. So, can it assist us that method? Yeah, I feel it could.
I feel that is one set of classes. The subsequent one is constructing confidence in care groups rapidly is in all people’s greatest curiosity. It is nice for the hospital. It offers them quicker returns and better confidence.
It is nice for the care groups. They construct confidence they usually get there quicker. And I feel loads of our instruments may help do this, may help speed up studying, not only for the surgeon however for others. After which lastly, I feel loads of these instruments permit for worth evaluation by the client utilizing their very own knowledge in their very own arms.
And that, I feel, builds confidence additionally and illuminates alternative for them, and that helps them and it helps us. So, for dV5 and type of the area we’re in proper now, that is the way you ought to consider it. One of many neat issues that Lonnie used to say, and he is proper is that each time you construct a functionality after which safe that, you may have it, you perceive it effectively. It opens a brand new door.
As a result of a surgeon, like Dr. Oh right here, we’ll take that new functionality and begin to discover it. The place can it lead me? What can I do subsequent? And I feel among the issues that we’re engaged on in dV5, among the imaging and augmented actuality issues will begin to encourage the following set of surgeons. And with that inspiration comes alternative.
Rick Sensible — Analyst
Nice. And if I may comply with up briefly with Jamie. Jamie, clearly, Ion and SP each had terrific years final yr. What accelerates — what drives the following part of progress there? And particularly, when is — what stage of gross sales or what has to occur? And is it a yr or 5 away? When are these two wonderful merchandise now not a margin drag? Thanks.
Jamie E. Samath — Chief Monetary Officer
Yeah. When it comes to the general enterprise, what’s driving procedures and income? If I have a look at Ion with 28,000 procedures in This fall, you’ll be able to see that is a run fee of over 100,000 procedures virtually solely within the U.S. So, you are beginning to rise up the adoption curve within the U.S. for Ion and a major remaining portion is in transthoracic needle aspiration when it comes to the strategy versus bronchoscopic approaches when it comes to the place we have adopted within the early interval.
So, what you see based mostly on the place you’re within the adoption curve within the U.S. for biopsy for Ion is clients will are inclined to extra deal with enhancements in utilization. And as you get to that time within the adoption curve, once more, biopsy within the U.S., you simply naturally on an S-curve begin to see process progress charges come down. And you have seen that in case you have a look at the final three or 4 quarters.
And so, for our Ion enterprise, type of subsequent set of focus. Clearly, we have got to complete the U.S. is the markets by which we’re launching internationally with the clearance in Europe, Korea, and China. And on a longer-term foundation, there may be the chance for Ion as a platform to get into new indications that may be within the lung first, and there is potential for different locations within the physique down the highway.
From a product price perspective, it’s a set of applications that take fairly a while. It is the on a regular basis battle within the manufacturing staff and there may be some engineering work that should occur to type of get to the product price. And I might say that is additionally within the midterm, in step with our total gross margin targets. With respect to SP adoption.
Once more, we have additionally received worldwide launches there. Europe and Japan, each have broad indications. You see Korea, which we have had within the market for a while, actually robust utilization. And so, for SP, it is actually as we glance to the U.S., is the extra indications.
We have got thoracic and colorectal. You will have the chance to increase that over some interval. You see the expansion fee accelerating properly in SP. Margin work in SP is, for example, not the identical stage of effort as Ion as a result of we’re extra leveraged.
The search and imaginative and prescient console of frequent with Xi, however by no means much less work to do. That can be, I characterize as one thing that occurs over the midterm.
Rick Sensible — Analyst
Thanks, Jamie.
Operator
Thanks. Our subsequent query comes from David Roman with Goldman Sachs. You could proceed.
David Roman — Analyst
Thanks and good afternoon, all people. I wished simply to begin with a remark you made within the ready remarks relating to competitors and promoting cycles. Is that this one thing that you simply’re observing right now as you discuss to clients outdoors the U.S. and even within the U.S.? Or are you simply calling out a theoretical influence of what may occur as new entrants come to market? After which I’ve one follow-up.
Jamie E. Samath — Chief Monetary Officer
We’ve got seen it clearly in China with the growing variety of home opponents there. I might say that when it comes to the influence of competitors to promoting cycles in different worldwide markets has been comparatively secure. However what you are seeing is an growing variety of opponents get clearances in numerous markets, together with within the U.S., there are a variety of opponents within the U.S. and clearly, there’s one bigger firm that is trying to make a submission in So, we’re simply acknowledging that as competitors will increase, there may be the chance outdoors of China, the promoting cycles may lengthen.
David Roman — Analyst
That is useful. And possibly simply type of a segue on that one. As you consider the chance in devices and equipment, both on a per-procedure foundation or a complete addressable market foundation, are you able to assist us assume by which elements of type of the surgical ecosystem you’ve got captured right now? And possibly give us some sense of the place that may be going over time? We perceive that is the fourth sensing piece of the launch of — with dV5 and the way which may influence principally an upgraded instrument and corresponding ASP inside that INA line. However as you have a look at type of different elements of the surgical ecosystem that you might seize to additional entrench your self, are you able to assist us perceive what these may be and possibly measurement a few of them? And the way type of you consider that when type of your advertising and marketing and strategic planning groups?
Gary S. Guthart — Chief Govt Officer and Director
Yeah. Possibly I will begin with type of the ideas we use to consider how we are able to carry extra worth to procedures we already take part in. And beneath, I feel you may have a modeling query, and I will let Jamie take that. On the principal aspect, we glance round and say, if there’s one thing happening within the working room that our clients are at the moment spending on, they’re shopping for from any individual else.
And we predict that both we’ve design capabilities or integration capabilities that may make for that have to be higher for them and value-creating. It is both clinically value-creating or it is economically value-creating, then we’ll search to do this. Generally in partnership, you see we’re doing that with Huron on the desk. And generally it is one thing that we’ll attempt to do ourselves take in-house and the way in which we have carried out some issues just like the cannula seals and stapling.
So, we glance throughout it. If we see an actual place the place it is true worth creation, not simply one thing the place it adjustments the income line by doing precisely what any individual else does, we’re not very fascinated with that. But when we predict the combination or the design creates a greater consequence for the client, both economically or clinically, hopefully, each, then we’ll step ahead and we’ll do this. We do not assume we’re carried out.
If you happen to have a look at da Vinci 5, you noticed some issues come into da Vinci 5 that have been benefited by integration, and we predict it is working nice. So, we search for these issues. They take some time. They don’t seem to be speedy.
So, our technique and our product planners are searching for value-creation alternatives there, however it would not begin with how briskly can the income progress be. It begins with what is the worth creation and what may that be. For sensing devices, force-reflecting devices are such an instance. They’re extra complicated.
They’ve the next ASP. We predict they bring about worth. We’ve got to reveal that worth and off we go. Jamie, I feel the modeling query is tremendous onerous, however I will provide you with a shot.
Jamie E. Samath — Chief Monetary Officer
So, I’d simply say that the 2 examples I might reference when it comes to the place you might, for example, get larger share of pockets, in case you can carry worth, our drive suggestions devices and insufflation each on da Vinci 5. Drive suggestions, we do not anticipate to be type of a broad provide till the top of ’25. So, the type of influence that has on I&A per process is gated by after we get to broad provide with respect to inflation. So, far, the proportion of circumstances that use that has been fairly excessive and that may have an effect as da Vinci 5 process volumes develop.
I’d simply say if I zoom out when it comes to I&A per process in complete, the bigger driver goes to be the process combine. A larger proportion of type of the place we see progress coming from is in benign procedures. Gary type of described that in more moderen outcomes. However when you consider cholecystectomy and different benign procedures, you may have a process combine dynamic that signifies that we predict, a minimum of over the following couple of years.
I&A per process drifts down slowly over time.
Gary S. Guthart — Chief Govt Officer and Director
We’ve got time for only one final query.
Operator
Thanks. And our final query comes from Patrick Wooden with Morgan Stanley. You could proceed.
Patrick Wooden — Morgan Stanley — Analyst
Stunning. Thanks a lot. A little bit of a bizarre conceptual one. I am simply type of inquisitive about it.
However in case you consider the efficiencies out of your put in base density. So, over time, as you are inserting an increasing number of techniques and in particular person areas and areas, the put in base density goes up. Is there actually a margin implication for that from extra efficiencies in promoting into the client base, and servicing the techniques? Are you able to see that in some areas or areas or markets the place you’ve got received loads of density versus these the place you may have barely much less scale? I am simply conceptually making an attempt to grasp the impact of that over the long run. Thanks.
Jamie E. Samath — Chief Monetary Officer
Properly, usually, the I&A income are at greater margins than capital. And so, as you drive utilization progress, then a larger proportion of the income over some interval comes from the upper revenue streams. Properly, let me ask Patrick. Is that the essence of your query?
Patrick Wooden — Morgan Stanley — Analyst
It was extra across the service and the effectivity of driving into these current accounts quite than the combination between the 2.
Gary S. Guthart — Chief Govt Officer and Director
I will reply rapidly simply in gentle of time. We do get some benefits of scale with geographic density when it comes to price to assist an account. So, service, service depots, gross sales assist, coaching assist, as that turns into extra dense, it does give us some price benefits to serve them. Is that the place you are headed?
Patrick Wooden — Morgan Stanley — Analyst
That is the way in which. Thanks a lot.
Gary S. Guthart — Chief Govt Officer and Director
OK. Thanks a lot. That was our final query. In closing, we imagine there is a substantial and sturdy alternative to essentially enhance surgical procedure and acute intervention.
Our groups proceed to work carefully with hospitals, physicians, and care groups in pursuit of what our clients have termed the Quintuple Purpose: higher, extra predictable affected person outcomes, higher experiences for sufferers which can be experiences for his or her care groups, which can be entry to nice care and finally, a decrease complete price of care. We imagine worth creation in surgical procedure and acute care is foundationally human. It flows from respect for and understanding of sufferers and care groups, their wants, and their setting. At Intuitive, we envision a way forward for care that’s much less invasive and profoundly higher the place illnesses are recognized earlier and handled rapidly so sufferers can get again to what issues most.
Thanks to your assist on this extraordinary journey. And we look ahead to speaking with you once more in three months.
Operator
[Operator signoff]
Period: 0 minutes
Name individuals:
Brandon Lamm — Senior Supervisor, Investor Relations
Gary S. Guthart — Chief Govt Officer and Director
Jamie E. Samath — Chief Monetary Officer
Daniel Oh — Vice President and Senior Medical Officer
Larry Biegelsen — Analyst
Gary Guthart — Chief Govt Officer and Director
Jamie Samath — Chief Monetary Officer
Robbie Marcus — Analyst
Travis Steed — Analyst
Rick Sensible — Analyst
David Roman — Analyst
Patrick Wooden — Morgan Stanley — Analyst
This text is a transcript of this convention name produced for The Motley Idiot. Whereas we try for our Silly Greatest, there could also be errors, omissions, or inaccuracies on this transcript. As with all our articles, The Motley Idiot doesn’t assume any accountability to your use of this content material, and we strongly encourage you to do your individual analysis, together with listening to the decision your self and studying the corporate’s SEC filings. Please see our Terms and Conditions for added particulars, together with our Compulsory Capitalized Disclaimers of Legal responsibility.
The Motley Idiot has positions in and recommends Intuitive Surgical. The Motley Idiot has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
